Data Availability
The results of this study are preliminary and the study is ongoing. Access to patient-level data with qualified external researchers may be available upon request once the trial is complete.
Posted July 25, 2021.
Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial
